Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Is Second Biologic Titan To Resolve Trade Secret Suit; Former Employees Still On Hook

Executive Summary

Genentech reaches memorandum of understanding with JHL Biotech involving four biosimilars while continuing its suit against former employees; Amgen settlement with Coherus ended litigation entirely.

You may also be interested in...



Fate Of JHL Biotech's Biosimilars Uncertain As Judge Bars Use Of Genentech Trade Secrets

Court denies JHL motion to dismiss trade secret theft suit, bars development or sale of biosimilars that rely on information from Genentech documents; trial scheduled to begin in November 2020.

Teva US settles with Apotex on collusion

Teva and Apotex have settled litigation in the US over allegations Teva’s former senior director of regulatory affairs for US generics, Barinder Sandhu, misappropriated trade secrets and shared them with Apotex’ erstwhile chief executive officer Jeremy Desai while the pair were in “a romantic relationship”.

Amgen Alleges 'Massive Conspiracy' By Employees Who Joined Coherus And KBI

Details emerge on the breadth of Amgen's complaint against Coherus and former Amgen employees; trade secrets on Neulasta pricing and contract strategies allegedly stolen via USB drives.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS017586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel